These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3320951)

  • 1. [Immunology of myeloma].
    Bataille R; Klein B; Rossi JF
    Nouv Rev Fr Hematol (1978); 1987; 29(4):255-64. PubMed ID: 3320951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homing mechanisms in the biology of multiple myeloma.
    Van Camp B; Van Riet I
    Verh K Acad Geneeskd Belg; 1998; 60(3):163-94. PubMed ID: 9803879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma: biology of the disease.
    Mahindra A; Hideshima T; Anderson KC
    Blood Rev; 2010 Nov; 24 Suppl 1():S5-11. PubMed ID: 21126636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Special Education: Aplastic Anemia.
    Teramura M; Mizoguchi H
    Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease.
    Pilarski LM; Giannakopoulos NV; Szczepek AJ; Masellis AM; Mant MJ; Belch AR
    Clin Cancer Res; 2000 Feb; 6(2):585-96. PubMed ID: 10690543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of osteoblast suppression in multiple myeloma.
    Stewart JP; Shaughnessy JD
    J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma and other differentiated B-cell disorders.
    Giles FJ
    Curr Opin Hematol; 1994 Jul; 1(4):278-84. PubMed ID: 9371294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow kinetic studies on three patients with myelomatosis. Indications for malignant proliferation within both the plasma cell and lymphoid cell compartments.
    Mellstedt H; Killander D; Pettersson D
    Acta Med Scand; 1977; 202(5):413-7. PubMed ID: 335796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
    Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G
    Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
    Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
    Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures.
    Peest D; Hölscher R; Weber R; Leo R; Deicher H
    Clin Exp Immunol; 1989 Feb; 75(2):252-7. PubMed ID: 2784737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key differentiation steps in normal B cells and in myeloma cells.
    Zubler RH
    Semin Hematol; 1997 Jan; 34(1 Suppl 1):13-22. PubMed ID: 9122741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
    Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
    Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell malignancy and monoclonal gammopathy, and idiotype of cell surface and serum immunoglobulin.
    Sugai S; Takiguchi T; Hirose Y; Konaka Y; Shimizu S; Konda S
    Jpn J Clin Oncol; 1983 Sep; 13(3):533-42. PubMed ID: 6417376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma.
    Perri RT; Oken MM; Kay NE
    J Lab Clin Med; 1982 Apr; 99(4):512-9. PubMed ID: 6460827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.
    Pellat-Deceunynck C; Barillé S; Puthier D; Rapp MJ; Harousseau JL; Bataille R; Amiot M
    Cancer Res; 1995 Aug; 55(16):3647-53. PubMed ID: 7543019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.